Table 13.
Distribution of Histologically-Confirmed Brain and Other Central Nervous System Tumors by WHO Grade Completeness, Treatment Information Completeness, and Histology, CBTRUS Statistical Report: U.S. Cancer Statistics – NPCR and SEER, 2014–2018
| Histology | Number of Newly Diagnosed Tumors | Histologically Confirmed (%)a | WHO Grade Completeness (%)b | Assigned WHO Gradec | Radiation Information Completenessd (%) | Surgical Extent of Resection Information Completenesse(%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete | Incomplete | Not Applicable | WHO Grade I | WHO Grade II | WHO Grade III | WHO Grade IV | |||||
| Diffuse Astrocytic and Oligodendroglial Tumors | 83,124 | 94.2% | 90.6% | 9.3% | 0.1% | 0.5% | 11.2% | 13.5% | 74.9% | 63.2% | 99.6% |
| Diffuse astrocytoma | 7,729 | 92.2% | 84.5% | 15.4% | 0.1% | 3.0% | 70.4% | 16.4% | 10.2% | 47.7% | 99.4% |
| Anaplastic astrocytoma | 7,175 | 99.3% | 94.7% | 5.3% | 0.1% | 0.1% | 2.0% | 89.6% | 8.3% | 73.8% | 99.6% |
| Glioblastoma | 61,699 | 93.5% | 90.6% | 9.3% | 0.1% | 0.2% | 0.2% | 0.7% | 98.9% | 65.4% | 99.7% |
| Oligodendroglioma | 3,706 | 96.8% | 92.6% | 7.4% | 0.0% | 1.5% | 89.3% | 6.6% | 2.6% | 37.6% | 99.5% |
| Anaplastic oligodendroglioma | 1,839 | 99.1% | 94.5% | 5.5% | 0.0% | 0.0% | 3.2% | 89.5% | 7.3% | 69.3% | 99.5% |
| Oligoastrocytic tumors | 976 | 98.6% | 93.3% | 6.7% | 0.0% | 1.1% | 47.1% | 42.5% | 9.2% | 60.0% | 99.8% |
| Other Astrocytic Tumors | 6,213 | 87.1% | 86.6% | 13.0% | 0.4% | 85.6% | 10.6% | 3.1% | 0.7% | 7.2% | 99.6% |
| Pilocytic astrocytoma | 5,303 | 88.8% | 87.3% | 12.3% | 0.4% | 94.4% | 4.5% | 0.8% | 0.3% | 5.5% | 99.6% |
| Unique astrocytoma variants | 910 | 77.3% | 82.0% | 17.9% | 0.1% | 22.9% | 53.9% | 19.9% | 3.3% | 17.2% | 99.4% |
| Malignant | 544 | 98.3% | 85.1% | 14.7% | 0.2% | 2.4% | 68.2% | 25.2% | 4.2% | 27.4% | 99.3% |
| Non-Malignant | 366 | 45.9% | 72.0% | 28.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 1.0% | 100.0% |
| Ependymal Tumors | 6,926 | 87.2% | 87.0% | 13.0% | 0.1% | 36.3% | 47.9% | 14.7% | 1.0% | 24.2% | 99.8% |
| Malignant | 3,967 | 93.5% | 89.3% | 10.6% | 0.1% | 2.6% | 72.8% | 23.2% | 1.4% | 36.0% | 99.9% |
| Non-Malignant | 2,959 | 78.9% | 83.2% | 16.7% | 0.0% | 93.9% | 5.6% | 0.3% | 0.3% | 7.9% | 99.6% |
| Other Gliomas | 8,575 | 39.3% | 51.5% | 47.4% | 1.1% | 12.6% | 24.9% | 21.1% | 41.4% | 27.2% | 99.0% |
| Glioma malignant, NOS | 8,471 | 38.6% | 51.3% | 47.5% | 1.2% | 12.7% | 23.9% | 20.9% | 42.5% | 27.1% | 99.0% |
| Other neuroepithelial tumors | 104 | 95.2% | 56.6% | 43.4% | 0.0% | 10.7% | 55.4% | 25.0% | 8.9% | 36.3% | 99.0% |
| Neuronal and Mixed Neuronal-Glial Tumors | 5,150 | 92.2% | 64.3% | 20.1% | 15.6% | 81.4% | 14.6% | 3.1% | 0.9% | 14.2% | 94.4% |
| Malignant | 978 | 98.4% | 22.2% | 6.7% | 71.1% | 28.6% | 7.5% | 51.6% | 12.4% | 56.5% | 73.9% |
| Non-Malignant | 4,172 | 90.8% | 75.7% | 23.8% | 0.5% | 84.4% | 15.0% | 0.3% | 0.2% | 4.3% | 99.7% |
| Choroid Plexus Tumors | 847 | 87.5% | 76.8% | 23.1% | 0.1% | 64.2% | 19.2% | 15.7% | 0.9% | 4.5% | 99.7% |
| Malignant | 131 | 97.7% | 80.5% | 18.8% | 0.8% | 6.7% | 1.9% | 86.5% | 4.8% | 13.9% | 100.0% |
| Non-Malignant | 716 | 85.6% | 76.0% | 24.0% | 0.0% | 76.9% | 23.1% | 0.0% | 0.0% | 2.7% | 99.7% |
| Tumors of the Pineal Region | 743 | 79.1% | 42.2% | 0.0% | 57.8% | -- | -- | -- | -- | 39.1% | 76.2% |
| Malignant | 422 | 98.1% | 43.4% | 0.0% | 56.6% | -- | -- | -- | -- | 63.2% | 76.6% |
| Non-Malignant | 321 | 54.2% | 39.2% | 0.0% | 60.8% | -- | -- | -- | -- | 7.7% | 75.3% |
| Embryonal Tumors | 3,252 | 98.2% | 81.1% | 18.2% | 0.7% | 0.4% | 0.2% | 1.4% | 98.0% | 61.4% | 99.5% |
| Tumors of Cranial and Paraspinal Nerves | 36,684 | 49.0% | 39.3% | 60.7% | 0.0% | 99.3% | 0.4% | 0.1% | 0.1% | 15.9% | 99.4% |
| Nerve sheath tumors | 36,647 | 49.0% | 39.3% | 60.7% | 0.0% | 99.3% | 0.4% | 0.1% | 0.1% | 15.9% | 99.4% |
| Malignant | 208 | 81.3% | 22.5% | 77.5% | 0.0% | 57.9% | 15.8% | 18.4% | 7.9% | 33.3% | 99.4% |
| Non-Malignant | 36,439 | 48.8% | 39.5% | 60.5% | 0.0% | 99.6% | 0.3% | 0.0% | 0.1% | 15.9% | 99.4% |
| Other tumors of cranial and paraspinal nerves | 37 | 40.5% | 33.3% | 66.7% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 2.9% | 100.0% |
| Tumors of Meninges | 174,568 | 38.7% | 79.4% | 20.5% | 0.1% | 79.8% | 18.0% | 2.0% | 0.1% | 6.6% | 99.6% |
| Meningiomas | 168,432 | 37.5% | 81.3% | 18.7% | 0.0% | 80.0% | 18.3% | 1.6% | 0.1% | 6.4% | 99.6% |
| Malignant | 1,699 | 78.8% | 86.2% | 13.8% | 0.0% | 19.1% | 17.3% | 62.4% | 1.2% | 36.6% | 98.4% |
| Non-Malignant | 166,733 | 37.1% | 81.2% | 18.8% | 0.0% | 81.4% | 18.3% | 0.2% | 0.1% | 6.1% | 99.6% |
| Mesenchymal tumors | 6,003 | 73.3% | 54.2% | 45.0% | 0.8% | 75.4% | 11.5% | 12.0% | 1.1% | 11.9% | 99.5% |
| Malignant | 769 | 96.0% | 41.8% | 54.1% | 4.1% | 11.6% | 16.4% | 65.6% | 6.4% | 48.0% | 98.8% |
| Non-Malignant | 5,234 | 69.9% | 56.7% | 43.1% | 0.2% | 85.0% | 10.8% | 4.0% | 0.3% | 6.4% | 99.7% |
| Primary melanocytic lesions | 133 | 87.2% | 11.2% | 82.8% | 6.0% | 61.5% | 23.1% | 0.0% | 15.4% | 40.0% | 98.3% |
| Lymphomas and Hematopoietic Neoplasms | 8,558 | 94.9% | 2.2% | 96.8% | 1.0% | 92.0% | 1.1% | 2.9% | 4.0% | 18.9% | 99.0% |
| Lymphoma | 8,478 | 94.9% | 2.1% | 97.1% | 0.7% | 91.9% | 1.2% | 2.9% | 4.0% | 18.6% | 99.1% |
| Other hematopoietic neoplasms | 80 | 92.5% | 2.7% | 68.9% | 28.4% | 100.0% | 0.0% | 0.0% | 0.0% | 49.2% | 89.2% |
| Germ Cell Tumors | 1,252 | 85.4% | 7.6% | 43.1% | 49.3% | 14.6% | 6.3% | 6.3% | 72.9% | 57.7% | 90.3% |
| Malignant | 1,085 | 87.6% | 7.9% | 40.3% | 51.8% | 4.7% | 7.0% | 7.0% | 81.4% | 65.2% | 90.0% |
| Non-Malignant | 167 | 70.7% | 5.0% | 66.4% | 28.6% | 100.0% | 0.0% | 0.0% | 0.0% | 7.7% | 92.4% |
| Tumors of Sellar Region | 77,084 | 45.5% | 10.3% | 0.4% | 89.3% | 100.0% | 0.0% | 0.0% | 0.0% | 2.8% | 75.7% |
| Tumors of the pituitary | 73,945 | 43.8% | 7.6% | 0.0% | 92.4% | 100.0% | 0.0% | 0.0% | 0.0% | 2.0% | 75.2% |
| Malignant | 125 | 64.0% | 8.0% | 0.0% | 92.0% | -- | -- | -- | -- | 18.6% | 68.8% |
| Non-Malignant | 73,820 | 43.8% | 7.6% | 0.0% | 92.4% | 100.0% | 0.0% | 0.0% | 0.0% | 2.0% | 75.2% |
| Craniopharyngioma | 3,139 | 83.8% | 35.6% | 4.3% | 60.0% | 100.0% | 0.0% | 0.0% | 0.0% | 21.3% | 81.2% |
| Unclassified Tumors | 18,797 | 17.1% | 5.9% | 85.7% | 8.4% | 63.4% | 7.4% | 6.9% | 22.3% | 3.7% | 94.6% |
| Hemangioma | 4,141 | 29.7% | 3.1% | 96.7% | 0.2% | 92.1% | 7.9% | 0.0% | 0.0% | 1.7% | 99.1% |
| Neoplasm, unspecified | 14,093 | 11.9% | 7.4% | 77.3% | 15.3% | 59.1% | 9.1% | 10.0% | 21.8% | 4.5% | 90.6% |
| Malignant | 6,692 | 8.1% | 8.5% | 86.3% | 5.2% | 15.6% | 15.6% | 22.2% | 46.7% | 8.3% | 87.6% |
| Non-Malignant | 7,401 | 15.5% | 6.8% | 73.1% | 20.0% | 89.2% | 4.6% | 1.5% | 4.6% | 2.6% | 92.1% |
| All other | 563 | 52.8% | 9.7% | 87.6% | 2.7% | 40.7% | 0.0% | 3.7% | 55.6% | 5.7% | 98.7% |
| Malignant | 83 | 97.6% | 28.9% | 66.3% | 4.8% | 27.3% | 0.0% | 4.5% | 68.2% | 33.8% | 98.8% |
| Non-Malignant | 480 | 45.0% | 2.3% | 95.8% | 1.9% | 100.0% | 0.0% | 0.0% | 0.0% | 0.3% | 98.6% |
| TOTAL | 431,773 | 54.5% | 64.5% | 20.1% | 15.5% | 39.7% | 14.4% | 8.1% | 37.7% | 19.5% | 95.7% |
| Malignant | 125,524 | 85.6% | 79.4% | 18.7% | 1.9% | 5.9% | 13.5% | 14.1% | 66.5% | 52.0% | 99.0% |
| Non-Malignant | 306,249 | 41.8% | 52.2% | 21.2% | 26.6% | 84.0% | 15.6% | 0.3% | 0.1% | 6.3% | 92.9% |
aHistologic confirmation includes tumors classified as diagnosis confirmed by positive histology, positive cytology, positive histology plus – positive immunophenotyping and/or positive genetic studies, or positive microscopic confirmation, method not specified.
bCompleteness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer’s Collaborative Staging schema, SSDI Clinical Grade (2018+ only) or SSDI Pathological Grade (2018+ only).
cGrade as recorded in the American Joint Commission on Cancer’s Collaborative Staging schema, SSDI Clinical Grade (2018+ only) or SSDI Pathological Grade (2018+ only).
dRadiation is defined using a recoded variable based on NAACCR Item #1360 (http://datadictionary.naaccr.org/default.aspx?c=10#136). Completeness is defined as having a value other than ‘none’ or ‘unknown.’
eSurgery is defined using a recoded variable based on NAACCR Item #1290.
(http://datadictionary.naaccr.org/default.aspx?c=10#1290). Please see the SEER site-specific surgery codes for more information on coding for this variable. (https://seer.cancer.gov/archive/tools/SEER2003.surg.prim.site.codes.pdf). Completeness is defined as having a value other than ‘unknown.’
- Percentages are not presented when category is not applicable.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; WHO, World Health Organization